Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | UBE2M | P61081 | 1/20 | 0.39 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877329 | 1.00 | MGLL (0.49) | MGLLRBP4SMOCYP3A4SLC6A7 | |
| SCHEMBL912647 | 0.87 | MGLL (0.60) | MGLLSMO | |
| SCHEMBL10175842 | 0.85 | SLC6A7 (0.57) | MGLLRBP4SMOCYP3A4SLC6A7 | |
| SCHEMBL14876973 | 0.81 | RIPK1 (0.46) | MGLLGHSRUBE2MDCUN1D1 | |
| SCHEMBL14877243 | 0.81 | RIPK1 (0.46) | MGLLGHSRUBE2MDCUN1D1 | |
| SCHEMBL14876971 | 0.80 | CYP3A4 (0.46) | MGLLRBP4CYP3A4GAAUBE2M | |
| SCHEMBL14877440 | 0.80 | CYP3A4 (0.46) | MGLLRBP4CYP3A4GAAUBE2M | |
| SCHEMBL912110 | 0.79 | MGLL (0.60) | MGLLSMO | |
| SCHEMBL14877286 | 0.79 | SLC6A7 (0.56) | MGLLRBP4SLC6A7GHSRUBE2M | |
| SCHEMBL10175214 | 0.79 | SLC6A7 (0.56) | MGLLRBP4SLC6A7GHSRUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | disclosed |
| US-20130102584-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102584-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | MGLL 3/4885RBP4 3666/4885SMO 2246/4885 |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | MGLL 1/4885RBP4 3301/4885SMO 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.